8-K: Delcath Systems Forecasts Revenue Surge and Medicaid Expansion for 2025

Delcath Systems projects significant revenue growth for 2025 and plans to expand patient access through a National Medicaid Drug Rebate Agreement.

Summary

• Delcath Systems anticipates total revenue between $94 million and $98 million for 2025.
• This represents an increase of over 150% compared to 2024.
• The company expects gross margins to be between 83% and 85%.
• Delcath plans to enter into a National Medicaid Drug Rebate Agreement (NDRA) with the Centers for Medicare & Medicaid Services, expected to take effect in the third quarter of 2025.
• The company anticipates positive adjusted EBITDA and cash flow in each quarter of 2025.
• Delcath projects a 200% increase in total HEPZATO treatment volume in 2025 compared to 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Delcath Systems, driven by strong revenue growth projections and strategic initiatives to expand market access. The company's focus on financial stability and innovation contributes to a favorable sentiment.

Positives

• The projected revenue growth of over 150% indicates strong market demand for Delcath's products.
• High gross margins between 83% and 85% suggest efficient cost management and pricing strategies.
• Entering the NDRA is expected to expand patient access and accelerate the adoption of HEPZATO.
• Anticipated positive adjusted EBITDA and cash flow in each quarter of 2025 demonstrate financial stability.
• The projected 200% increase in HEPZATO treatment volume signifies growing clinical acceptance and utilization.

Risks

• The company's ability to successfully enter into the NDRA and the potential impact on its business and operations are uncertain.
• Successful commercialization of the HEPZATO KIT is subject to various factors, including market acceptance and competition.
• The company's ability to manage the HEPZATO KIT supply chain and secure adequate supply of critical components is crucial.
• Successful FDA inspections of the company's and its third-party suppliers'/manufacturers' facilities are necessary.
• The company must successfully implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy.
• Obtaining reimbursement for the HEPZATO KIT is essential for its widespread adoption.
• Entering into necessary purchase and sale agreements with users of the HEPZATO KIT is critical.

Future Outlook

Delcath Systems anticipates significant revenue growth and improved financial performance in 2025, driven by increased adoption of HEPZATO and participation in the Medicaid Drug Rebate Program.

Management Comments

• Gerard Michel, Chief Executive Officer of Delcath, stated that entering into the NDRA simplifies Medicaid access and enables eligible hospitals to access 340B drug pricing, which is expected to expand treatment availability and accelerate adoption of HEPZATO in the United States.

Industry Context

Delcath's focus on liver-directed cancer therapies aligns with the growing trend of targeted treatments in oncology. The company's expansion into the Medicaid market reflects a broader industry effort to improve patient access to innovative therapies.

Comparison to Industry Standards

• Comparing Delcath's projected revenue growth of 150% to other oncology companies, such as Exact Sciences which has seen growth of 20% in the last year, indicates a strong market position and potential for further expansion.
• The gross margin guidance of 83-85% is competitive with other specialty pharmaceutical companies like Horizon Therapeutics, which has gross margins around 70-80%.

Stakeholder Impact

• Shareholders can expect potential value appreciation due to projected revenue growth and improved financial performance.
• Patients will benefit from increased access to HEPZATO KIT through the Medicaid Drug Rebate Program.
• Employees may experience job security and growth opportunities due to the company's expansion.
• Suppliers may see increased demand for their products and services.
• Creditors can expect improved financial stability and repayment capacity.

Next Steps

• Delcath plans to finalize and implement the National Medicaid Drug Rebate Agreement (NDRA).
• The company will continue to focus on commercializing HEPZATO KIT and expanding its market reach.
• Delcath will monitor and manage its supply chain to ensure adequate availability of HEPZATO KIT.
• The company will undergo FDA inspections of its facilities and those of its third-party suppliers/manufacturers.
• Delcath will implement and manage the HEPZATO KIT Risk Evaluation and Mitigation Strategy.

Key Dates

Keywords

HEPZATO KIT, CHEMOSAT, Delcath Systems, Revenue Guidance, Medicaid, NDRA, Liver Cancer, Oncology